Caribou Biosciences (CRBU) Other Non-Current Liabilities (2020 - 2022)
Caribou Biosciences (CRBU) posted quarterly Other Non-Current Liabilities of $9000.0 for Q1 2022, down 47.06% quarter-over-quarter from $17000.0 in Q4 2021.
Caribou Biosciences (CRBU) Other Non-Current Liabilities (2020 - 2022) Analysis & Trends
Caribou Biosciences (CRBU) has reported Other Non-Current Liabilities for 3 consecutive years, with $9000.0 the latest figure, recorded in Q1 2022.
- In Q1 2022, Other Non-Current Liabilities changed N/A year-over-year to $9000.0; the TTM figure through Mar 2022 stood at $9000.0 (changed N/A YoY), while the FY2021 annual figure was $17000.0, down 90.34% from the prior year.
- Other Non-Current Liabilities slipped to $9000.0 in Q1 2022 per CRBU's latest filing, from $17000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $176000.0 in Q4 2020 and bottomed at $9000.0 in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $103600.0 across 3 years, with a median of $153000.0 in 2021.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 90.34% in 2021 and fell as far as 90.34% in 2021.
- Caribou Biosciences' Other Non-Current Liabilities stood at $176000.0 in 2020, then sank by 90.34% to $17000.0 in 2021, then tumbled by 47.06% to $9000.0 in 2022.
- Business Quant data shows CRBU's Other Non-Current Liabilities at $9000.0 in Q1 2022, $17000.0 in Q4 2021, and $153000.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | 17,000.00 |
| Sep 30, 2021 | 153,000.00 |
| Jun 30, 2021 | 163,000.00 |
| Dec 31, 2020 | 176,000.00 |